Kaleido Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kaleido Biosciences Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11047
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kaleido Biosciences Inc (Kaleido Biosciences) is a developer of human microbiomes for the treatment of infectious, rare genetic, inflammatory, oncology and metabolic diseases. The company’s human microbiome is a metabolic engine which is developed from healthy and diseased humans using various biotechnology techniques. It uses synthetic chemistry to design novel compounds with unique capability to improve specific outputs of the microbiome. Kaleido Biosciences’ novel chemistries are screened in its ex vivo microbiome platform that allows intact human microbiomes to be assayed in a high-throughput laboratory environment. The company discovers new chemistries to modulate the entire metabolic profile of the microbiome. Kaleido Biosciences is headquartered in Bedford, Massachusetts, the US.

Kaleido Biosciences Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Kaleido Biosciences Raises USD101 Million in Series C Venture Financing 10
Kaleido Biosciences Raises Additional Funds through Venture Financing 12
Partnerships 13
Kaleido Biosciences Enters into Agreement with CoreBiome 13
Kaleido Biosciences Inc – Key Competitors 14
Kaleido Biosciences Inc – Key Employees 15
Kaleido Biosciences Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
Aug 21, 2018: Kaleido Biosciences names Alison Lawton as chief executive officer 17
Apr 23, 2018: Kaleido Biosciences Names Joshua Brumm As Chief Financial Officer 19
Mar 26, 2018: Kaleido Biosciences Announces New Leadership Team 20
Jan 03, 2018: Kaleido Biosciences Announces Appointment of Wendy Arnold as Senior Vice President, Human Resources 21
Dec 12, 2017: Kaleido Biosciences Expands Leadership Team with Appointment of Alison Lawton as President and Chief Operating Officer 22
Sep 18, 2017: Kaleido Biosciences Announces Appointment of Mike Bonney as CEO and Completion of Additional Fundraising 23
Other Significant Developments 24
Sep 18, 2017: Flagship Pioneering Unveils Kaleido Biosciences and First Chemistry Platform for Microbiome Health 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kaleido Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kaleido Biosciences Raises USD101 Million in Series C Venture Financing 10
Kaleido Biosciences Raises Additional Funds through Venture Financing 12
Kaleido Biosciences Enters into Agreement with CoreBiome 13
Kaleido Biosciences Inc, Key Competitors 14
Kaleido Biosciences Inc, Key Employees 15

List of Figures
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Kaleido Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ROHM Co Ltd (6963):企業の財務・戦略的SWOT分析
    ROHM Co Ltd (6963) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Hindustan Oil Exploration Co Ltd (HINDOILEXP):企業の財務・戦略的SWOT分析
    Summary Hindustan Oil Exploration Co Ltd (HOEC) is an oil and gas exploration and development company. The company’s business activities include exploration and development of hydrocarbons crude oil and natural gas. It offers geological and geophysical services related to the exploration of oil and …
  • African Development Bank Group:企業の戦略的SWOT分析
    African Development Bank Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • EP Energy Corp (EPE):石油・ガス:M&Aディール及び事業提携情報
    Summary EP Energy Corp (EP Energy) is an oil and gas exploration and production company that offers acquisition and development of unconventional onshore oil and natural gas properties in the US. The company operates Altamont program, Eagle Ford program and Wolfcamp program. Its Eagle Ford program i …
  • Faron Pharmaceuticals Oy (FARN)-製薬・医療分野:企業M&A・提携分析
    Summary Faron Pharmaceuticals Oy (Faron Pharma) is a drug company that carries out clinical stage drug discovery and development. The company's product portfolio includes traumakine; clevegen; farbetic, an AOC3 inhibitor and D-ARDS, a diagnostic tool. Its traumakine clinical programme manages the tr …
  • National Jewish Health:製薬・医療:M&Aディール及び事業提携情報
    Summary National Jewish Health (NJH), formerly National Jewish Medical and Research Center is a healthcare service provider that offers treatment for pulmonary, cardiac, immune and related disorders. The center conducts programs in the therapeutic areas of allergy, asthma, bronchicardiology, bronchi …
  • Hansen Medical, Inc.:企業のM&A・事業提携・投資動向
    Hansen Medical, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hansen Medical, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Sidi Kerir Petrochemicals Co (SKPC):企業の財務・戦略的SWOT分析
    Summary Sidi Kerir Petrochemicals Co (Sidpec), a subsidiary of Egyptian Petrochemicals Holding Co, is a chemical company that manufactures and distributes petrochemical products. The company offers high density polyethylene and linear low density polyethylene which are used in plastic applications i …
  • Hitachi Koki Co., Ltd.:企業の戦略的SWOT分析
    Hitachi Koki Co., Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Xactware Solutions Inc:企業の戦略的SWOT分析
    Xactware Solutions Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Cellerant Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Cellerant Therapeutics Inc (Cellerant) develops novel immunotherapies for oncology and blood-related disorders. Its lead product, CLT-008, is a myeloid progenitor cell therapy which is in Phase 2 clinical development in patients with acute myeloid leukemia (AML). Cellerant develops various c …
  • UltraTech Cement Ltd:企業の戦略・SWOT・財務情報
    UltraTech Cement Ltd - Strategy, SWOT and Corporate Finance Report Summary UltraTech Cement Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Murad LLC:企業の戦略・SWOT・財務分析
    Murad LLC - Strategy, SWOT and Corporate Finance Report Summary Murad LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Valeura Energy Inc (VLE):石油・ガス:M&Aディール及び事業提携情報
    Summary Valeura Energy Inc (Valeura) is an upstream oil and gas company that explores for, develops and produces oil and natural gas. It operates mainly in the Thrace Basin in the northwest of Turkey pursuing conventional shallow natural gas, unconventional tight gas and a basin-centered gas accumul …
  • Biotest AG (BIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Biotest AG (Biotest) provides pharmaceutical and biotherapeutic drugs. It develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products comprise clotting factors, immunoglobulins, albumin and monoclon …
  • Oil and Natural Gas Corporation Limited:戦略・SWOT・企業財務分析
    Oil and Natural Gas Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Oil and Natural Gas Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • San Miguel Power Association, Inc.:企業の戦略的SWOT分析
    San Miguel Power Association, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Southwestern Energy Company:企業の戦略・SWOT・財務情報
    Southwestern Energy Company - Strategy, SWOT and Corporate Finance Report Summary Southwestern Energy Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Irkut Corporation (IRKT):企業の財務・戦略的SWOT分析
    Irkut Corporation (IRKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Strategic Oil & Gas Ltd (SOG):企業の財務・戦略的SWOT分析
    Summary Strategic Oil & Gas Ltd (Strategic Oil & Gas) is an upstream oil and gas exploration and development company. The company acquires, explores, operates, manages, and develops crude oil and natural gas assets. It holds interests and operates its oil and gas exploration projects such as Marlowe …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆